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BRIEF REPORTS
Presentation of Severe Acute Respiratory Syndrome-Coronavirus 2
Infection as Cholestatic Jaundice in Two Healthy Adolescents
Adriana Perez, MD1, Debora Kogan-Liberman, MD1, Shari Sheflin-Findling, DO2, Aileen Raizner, MD1, Kanya L. Ahuja, MBBS2,
and Nadia Ovchinsky, MD, MBA1
Liver abnormalities in severe acute respiratory syndrome-coronavirus 2 infection, including hepatitis and cholestasis,
have been observed in adults and are associated with worse outcomes. We describe 2 adolescents with cholestasis
and hepatitis with mild presentation of severe acute respiratory syndrome-coronavirus 2 lacking typical symptoms. Our
intention is to raise index of suspicion for testing and protective equipment use. (J Pediatr 2020;226:278-80).

A

s of June 25, 2020, the coronavirus disease 2019
(COVID-19) caused by severe acute respiratory
syndrome-coronavirus 2 (SARS-CoV-2) resulted in
>9.4 million confirmed cases worldwide and >482 000 deaths
worldwide, including >2.3 million cases and >121 000 deaths
reported in the US, among which were 84 pediatric deaths in
persons <24 years of age by June 13 2020.1-3
In the US, 22% of the population is comprised of infants,
children, and adolescents <18 years of age.4 SARS-CoV-2 affects adults and children in dramatically different ways. Early
pediatric epidemiologic data of 3 studies with 1391 and 2135
children from Wuhan, China, and 2572 US children demonstrated that the majority had mild symptoms compared with
adults, but may serve as vectors of transmission in society.4-6
North American pediatric intensive care units collaborative
report from March and April 2020 confirmed these findings,
but also noted that severe illness in children is significant,
albeit far less frequent, compared with adults.7 Infants and
children with comorbidities were particularly vulnerable to
COVID-19.6–8
No previous study to date has reported an association between COVID-19 and acute cholestasis in the pediatric population. The incidence of liver injury in adult patients with
COVID-19 ranges from 14.8% to 53%, being more significant in severe cases and ranging up to 78% among fatal
cases.9 Liver abnormalities described included elevation of
serum alanine aminotransferase (ALT) and aspartate
aminotransferase (AST), mildly elevated bilirubin levels,
high gamma-glutamyl transferase, and low albumin levels
(2.6-3.3 g/L).9,10
We present 2 cases of acute hepatitis with clinically
apparent jaundice and cholestasis without biliary obstruction
associated with SARS-CoV-2 infection. Both adolescents
lacked other typical features of COVID-19 respiratory tract
infection and had a mild disease course. Given significant
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variability of COVID-19 symptoms in children, providers
had a high index of suspicion and tested these patients with
an unusual presentation.

Methods
Institutional review board approval was obtained at Albert Einstein College of Medicine. These case reports were exempt from
institutional review board oversight at Feinstein Institutes for
Medical Research of Northwell Health. Patients described
here are unique to this report and are excluded from our
registry of COVID-19 patients. Demographic information
and clinical, laboratory, and imaging results were examined.
Case 1
A 16-year-old boy presented to the emergency department
(ED) of the Children’s Hospital at Montefiore in the Bronx,
New York, with 1 day of scleral icterus, epigastric abdominal
pain, nausea, 2 episodes of nonbloody, nonbilious emesis,
decreased oral intake, and dark urine. No respiratory symptoms or diarrhea were present. The patient and family reported staying at home in the preceding 3 weeks without
any exposure to sick contacts, a known COVID-19 case,
essential workers, or travel. Patient denied any drug or
alcohol use.
His medical history was significant for elevated serum
hepatic enzymes with acute cholestasis 3 years previously,
secondary to cholelithiasis for which he underwent cholecystectomy. His hepatic enzymes and bilirubin level had normalized. He was found to carry reduced activity in uridine
diphosphate-glucuronosyltransferase A1 gene associated
with Gilbert syndrome.11
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Table. Patient characteristics
Characteristics

Patient 1

Patient 2

Age, years
Sex
Weight, kg
Body mass index, kg/m2 (percentile)
Symptoms
Jaundice/icterus
Dark urine
Respiratory
Abdominal pain
Nausea/vomiting
Diarrhea
Fever
Laboratory values
Total bilirubin, mg/dL
Direct bilirubin, mg/dL
Gamma-glutamyl transferase, U/L
AST, U/L
ALT, U/L
Alkaline phosphatase, U/L
Albumin, g/dL
Platelet count, k/mL
International normalized ratio
White blood cell count, k/mL
Absolute lymphocyte count, cells/mL
C-reactive protein, mg/dL
Lipase, U/L

16
Male
59.7
23.61 (79)

17
Female
56.9
21.2 (55)

+
+
–
+
+
–
–

+
+
–
–
–
+
+

3.6
2.2
319
655
767
259
4.8
244
1.1
4.0
1240
<0.5
43

3.4
1.0
147
154
294
198
4.0
210
1.18
10.86
5930
–
39.3

Upon arrival to the ED, he was noted to have tachycardia to
128 bpm and was afebrile. Physical examination was notable
for scleral icterus, dry mucous membranes, and epigastric
tenderness. He was found to have significantly elevated serum
AST and ALT at 655 U/L and 767 U/L, respectively. Conjugated
hyperbilirubinemia was also detected with total bilirubin/
direct bilirubin at 3.6/2.2 mg/dL. Gamma-glutamyl transferase
was elevated at 301 U/L. Hepatic synthetic function was normal
(albumin, 5.0 g/dL; international normalized ratio, 1.1). Remaining evaluation, including inflammatory markers, was unremarkable (Table). Ultrasound examination of the liver and
biliary tree was normal.
Given his prior history of cholelithiasis with cholecystectomy and concern for an obstructive process, magnetic resonance cholangiopancreatography was obtained to further
assess for any anatomic abnormalities and revealed no
evidence of intrahepatic or extrahepatic ductal dilatation or
biliary stricture. Although he had no fever or respiratory
symptoms, COVID-19 hepatitis was considered in the
differential diagnosis, and his SARS-CoV-2 polymerase chain
reaction test was positive.
The patient was admitted for monitoring. No treatment
targeting COVID-19 was initiated owing to a lack of supporting evidence and otherwise well-being. Airborne/special contact precautions were maintained during his hospitalization.
The patient never developed respiratory or other systemic inflammatory symptoms. After 24 hours, his direct bilirubin
level decreased to 0.4 mg/dL. Three weeks after discharge,
AST/ALT decreased to 47/76 U/L and total bilirubin remained elevated at 1.7 mg/dL with normal direct fraction
of <0.5 mg/dL (consistent with prior diagnosis of Gilbert).
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Case 2
A 17-year-old previously healthy young woman presented to
the ED at Cohen Children’s Medical Center in New York’s Nassau County with 4 days of fever, acute onset of jaundice, and
dark urine. She had developed urinary urgency without fever
or dysuria 6 days before presentation. She was seen at a clinic,
where a urine culture was obtained that was negative. Four days
before presentation, her urine turned dark orange/brown and
she developed fever with maximum temperature of 103 F.
She also complained of chills and night sweats, and had an
episode of nonbloody diarrhea. On the day of presentation,
she noted that the whites of her eyes seemed to be yellow. No
respiratory symptoms (cough, congestion, and/or difficulty
breathing) were present. She had no abdominal pain, nausea,
or vomiting. She no longer experienced urinary urgency or
dysuria. There was no prior history of cholestasis, jaundice,
or liver disease. She denied any drug or alcohol use. She
confirmed no exposure to a case of COVID-19 or recent travel.
In the ED, she had tachycardia to 111 bpm and was
afebrile. Physical examination revealed a nonobese female
with scleral icterus without abdominal tenderness. Laboratory test results revealed elevation of serum AST and ALT
to 154 and 294 U/L, respectively. One month prior, AST
and ALT levels obtained during annual physical examination
were normal (11 and 15 U/L, respectively). Total and direct
bilirubin levels were 3.4/1 mg/dL and gamma-glutamyl transferase was 147 U/L. Liver synthetic function, international
normalized ratio, albumin, and platelets were normal
(Table).
An abdominal ultrasound examination revealed hepatomegaly (16.1 cm span) with normal echogenicity and without
any gallstones, sludging, or bile duct dilation. SARS-CoV-2
polymerase chain reaction test on nasal specimen was positive. She was discharged home from the ED with close
follow-up. Two weeks later, serum AST and ALT levels
were 56 and 147 U/L respectively, with total and direct bilirubin levels of 0.6/0.2 mg/dL.

Discussion
Mild cholestasis in COVID-19 was described in a pediatric
patient from Wuhan, China.12 A 55-day-old infant with
pneumonia and acute cardiac injury developed mild hepatitis
(AST/ALT of 100/84 IU/L) and conjugated hyperbilirubinemia (total bilirubin/direct bilirubin 2/1.4 mg/dL), which
resolved with clinical improvement.12
The incidence of liver injury in adult patients with
COVID-19 can range from 14.8% to 78.0%.9 One study of
adults with severe COVID-19 admitted to the intensive
care unit did not report a significant difference in percentage
of patients with liver dysfunction between survivors and
nonsurvivors, although biochemical test results of the
nonsurvivors showed more abnormalities.13
The cause of liver injury can be multifactorial, from druginduced liver injury (owing to use of antiviral or antibiotic
agents, corticosteroids, and natural remedies), hepatic
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congestion associated with high positive end-expiratory pressure, and/or direct liver damage by virus-induced T lymphocytes.9,14 High levels of proinflammatory cytokine molecules
were found in patients with COVID-19 activating T-helper
1 cell response and inducing dysregulation of the innate immune response.9,14 A postmortem liver biopsy obtained in a
patient with COVID-19 from Wuhan, China, demonstrated
moderate microvesicular steatosis and mild lobular and portal activity, indicating either virus- or drug-induced liver
injury.9,15
Recent evidence indicates that angiotensin converting
enzyme II is likely the cell receptor of SARS-CoV-2.16,17
Chai et al were able to identify expression of angiotensin converting enzyme II within bile duct epithelial cells (cholangiocytes), but not hepatocytes in healthy liver tissues.18
Cholangiocytes are known to play an important role in liver
regeneration and immune response, which could be a mechanism underpinning acute cholestasis we observed.19
In our 2 cases of acute cholestasis with hepatitis, the patients
lacked typical features of COVID-19 such as fever, cough,
shortness of breath, myalgia, sore throat, or significant gastrointestinal symptoms, as well as any signs of inflammatory
dysregulation seen in multisystem inflammatory syndrome
in children.4,20 Both patients were nonobese adolescents
without underlying liver disease or other comorbidities.
Our patients had a mild clinical course. Extensive evaluation for cholestasis may not be necessary in otherwise healthy
pediatric patients with SARS-CoV-2 infection. Imaging can
be limited to those with symptoms concerning for biliary
obstruction. Further studies are needed to ascertain whether
a higher rate of cholestasis is associated with SARS-CoV-2
infection in children and adolescents. Recognition and identification of children and adolescents with acute cholestasis
secondary to SARS-CoV-2 is important for management,
appropriate infection control and proper use of personal
protective equipment. n
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